All eyes turn to loans after $16bn Roche bond success
Roche, the Swiss pharmaceutical group, on Wednesday issued $16bn of bonds to back its $42.1bn hostile bid for Genentech leading bankers to turn their attention to Europe’s loan market, where the borrower is also expected to raise debt.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
